At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCC Warrior Met Coal LLC
Post-Mkt 09-01 19:20:12 EDT
106.23
-2.01
-1.86%
盘后104.69
-1.54-1.45%
18:44 EDT
High110.00Low106.03Vol404.33K
Open108.02D1 Closing108.24Amplitude3.67%
Mkt Cap5.58BTradable Cap5.50BTotal Shares52.57M
T/O43.21MT/O Rate0.78%Tradable Shares51.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire  ·  09-01 19:00
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Tokio Marine HCC International Acquires UK-Based Direct Commercial
MT Newswires Live  ·  08-31 11:40
Tokio Marine HCC International Acquires UK-Based Direct Commercial
Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Dow Jones  ·  08-28
Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed
Stock News  ·  08-27
IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed
Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million
Reuters  ·  08-26
Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million
Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110
THOMSON REUTERS  ·  08-26
Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110
Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Dow Jones  ·  08-25
Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
GlobeNewswire  ·  08-25
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
Press Release: Antengene Announces 2026 Interim Results: Achieves First
Dow Jones  ·  08-24
Press Release: Antengene Announces 2026 Interim Results: Achieves First
Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304
Reuters  ·  08-22
Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
GlobeNewswire  ·  08-20
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
GlobeNewswire  ·  08-17
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
TIPRANKS  ·  08-15
Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
Press Release: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Dow Jones  ·  08-13
Press Release: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Dow Jones  ·  08-12
Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
RBC Capital Keeps Their Hold Rating on Warrior Met Coal (HCC)
TIPRANKS  ·  08-12
RBC Capital Keeps Their Hold Rating on Warrior Met Coal (HCC)
Warrior Met Coal (HCC) Updates 2026 Guidance, Is It Still Below Fair Value?
Simply Wall St.  ·  08-09
Warrior Met Coal (HCC) Updates 2026 Guidance, Is It Still Below Fair Value?
Alpha Metallurgical Q2 Adjusted Ebitda Misses Estimates on Lower Shipments
Reuters  ·  08-07
Alpha Metallurgical Q2 Adjusted Ebitda Misses Estimates on Lower Shipments
Warrior Met Coal Price Target Cut to $98.00/Share from $100.00 by UBS
Dow Jones  ·  08-07
Warrior Met Coal Price Target Cut to $98.00/Share from $100.00 by UBS
UBS Adjusts Warrior Met Coal Price Target to $98 From $100, Maintains Buy Rating
MT Newswires Live  ·  08-06
UBS Adjusts Warrior Met Coal Price Target to $98 From $100, Maintains Buy Rating

Introduction

Company Name.
Warrior Met Coal LLC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.
Issue price:
--